Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
India
/
Pharmaceuticals & Biotech
/
Mankind Pharma
MANKIND
Mankind Pharma
India's Rising Middle Class And Urbanization Will Reshape Healthcare Markets
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 17 Analysts
Published
10 Aug 25
Updated
15 Aug 25
0
Set Fair Value
0
votes
Share
AnalystHighTarget
's Fair Value
₹3,300.00
24.0% undervalued
intrinsic discount
15 Aug
₹2,506.60
Loading
1Y
9.9%
7D
1.6%
Author's Valuation
₹3.3k
24.0% undervalued
intrinsic discount
AnalystHighTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystHighTarget Fair Value
₹3.3k
24.0% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
0
203b
2019
2021
2023
2025
2027
2028
Revenue ₹203.0b
Earnings ₹39.1b
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
12.93%
Pharma revenue growth rate
0.55%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
12.73%
Calculation
₹39.08b
Earnings '28
x
54.55x
PE Ratio '28
=
₹2.13t
Market Cap '28
₹2.13t
Market Cap '28
/
451.15m
No. shares '28
=
₹4.73k
Share Price '28
₹4.73k
Share Price '28
Discounted to 2025 @ 12.73% p.a.
=
₹3.30k
Fair Value '25